Actively Recruiting

Early Phase 1
Age: 18Years - 65Years
All Genders
NCT04366518

Toward a Computationally-Informed, Personalized Treatment for Hallucinations

Led by Yale University · Updated on 2025-06-05

35

Participants Needed

1

Research Sites

576 weeks

Total Duration

On this page

Sponsors

Y

Yale University

Lead Sponsor

N

National Institute of Mental Health (NIMH)

Collaborating Sponsor

AI-Summary

What this Trial Is About

Auditory hallucinations are among the most distressing aspects of psychotic illness, and between 10 and 30% of people with hallucinations do not respond to antipsychotic medications. The authors have used computational modeling of behavior to link brain activity to development of auditory hallucinations in the hope of guiding new treatment development. The proposed studies take the first step toward individualized treatment approaches to hallucinations by attempting causal, pharmacological manipulation of relevant model parameters underlying these phenomena.

CONDITIONS

Official Title

Toward a Computationally-Informed, Personalized Treatment for Hallucinations

Who Can Participate

Age: 18Years - 65Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 18-65
  • English speaking
  • Right handedness
  • Diagnosed with schizophrenia, schizoaffective, schizophreniform, schizotypal, or brief psychotic disorder
  • History of auditory verbal hallucinations occurring at least weekly
Not Eligible

You will not qualify if you...

  • Current substance dependence or active use as determined by drug test
  • Any neurological, medical or developmental problem that significantly impairs cognition
  • Contraindications for MRI including metallic implants, pacemakers, history of accidents with metal, or claustrophobia
  • History of seizures
  • History of violence
  • History of suicide
  • Pregnancy confirmed by urine test
  • Concurrent participation in another intervention study
  • History of urinary retention
  • History of delirium
  • Current use of cholinergic or anticholinergic medication
  • History of asthma, diabetes, or cardiovascular disease
  • Evidence of cardiovascular disease on EKG
  • Use of dopamine-2 antagonists for less than 6 months to limit risk of extrapyramidal symptoms

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Connecticut Mental Health Center

New Haven, Connecticut, United States, 06519

Actively Recruiting

Loading map...

Research Team

A

Albert Powers, MD, PhD

CONTACT

S

Silmilly Toribio

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

CROSSOVER

Primary Purpose

BASIC_SCIENCE

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here